Literature DB >> 28608116

Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.

Kotaro Yamashita1, Yukinori Kurokawa2, Kazuyoshi Yamamoto3, Masashi Hirota4, Ryohei Kawabata5, Jota Mikami6, Toru Masuzawa7, Shuji Takiguchi1, Masaki Mori1, Yuichiro Doki1.   

Abstract

BACKGROUND: Curative gastrectomy followed by adjuvant S-1 chemotherapy for 12 months is one of the standard treatments for patients with pathological stage (p-stage) II or III gastric cancer. Although some patients have difficulty maintaining compliance with adjuvant S-1, the risk factors for poor compliance are unknown.
METHODS: We retrospectively analyzed the data of patients at 21 institutions who underwent curative gastrectomy followed by adjuvant S-1 for p-stage II or III gastric cancer. Patients who had a recurrence within 12 months after surgery were excluded from the analysis. Associations between clinicopathological factors and both 12-month compliance and the cumulative continuation rate of S-1 were analyzed.
RESULTS: Of 359 patients, 252 (70.2%) continued adjuvant S-1 until 12 months after surgery. Older age (>65 years) and postoperative infectious complications (Clavien-Dindo grade III or higher) were significantly correlated with low compliance with S-1 for 12 months (p = 0.008 and p = 0.042). These two factors also showed significant associations with low cumulative continuation rate (log-rank p < 0.001 and p = 0.018). Continuation rates at 12 months after surgery in patients aged ≤60 years, 61-65, 66-70, 71-75, and 76-80 years were 81.5, 75.9, 65.4, 58.7, and 62.9%, respectively. Type of gastrectomy or body weight loss at 1 month after surgery did not affect either 12-month compliance or the cumulative continuation rate of S-1.
CONCLUSIONS: Older age, especially over 65 years, and postoperative infectious complications were independent risk factors for poor compliance with adjuvant S-1 chemotherapy for gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28608116     DOI: 10.1245/s10434-017-5923-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Usefulness of an S-1 dosage formula: an exploratory analysis of randomized clinical trial (JCOG1001).

Authors:  Takeshi Kawakami; Junki Mizusawa; Hiroko Hasegawa; Hiroshi Imazeki; Kazuki Kano; Yuya Sato; Satoru Iwasa; Shuji Takiguchi; Yukinori Kurokawa; Yuichiro Doki; Narikazu Boku; Takaki Yoshikawa; Masanori Terashima
Journal:  Gastric Cancer       Date:  2022-06-29       Impact factor: 7.701

2.  Body Mass Index and Prognosis of Patients With Stage II/III Gastric Cancer After Curative Gastrectomy: Completion of Perioperative Adjuvant Chemotherapy May Be a Confounding Factor.

Authors:  Wei Peng; Jing Dai; Chao-Chan Liu; Dian Liu; Hua Xiao
Journal:  Front Oncol       Date:  2022-06-13       Impact factor: 5.738

3.  Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).

Authors:  Kazumasa Fujitani; Shigeyuki Tamura; Yutaka Kimura; Jin Matsuyama; Hiroshi Imamura; Kazuyoshi Yamamoto; Junya Fujita; Shohei Iijima; Shugo Ueda; Yukinori Kurokawa; Toshio Shimokawa; Taroh Satoh
Journal:  Gastric Cancer       Date:  2019-10-30       Impact factor: 7.370

4.  The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study.

Authors:  Sung Ho Jang; Young Jae Jung; Min Gyu Kim; Sung Joon Kwon
Journal:  J Gastric Cancer       Date:  2018-03-14       Impact factor: 3.720

Review 5.  Nutrition update in gastric cancer surgery.

Authors:  Takeshi Kubota; Katsutoshi Shoda; Hirotaka Konishi; Kazuma Okamoto; Eigo Otsuji
Journal:  Ann Gastroenterol Surg       Date:  2020-06-08

6.  Who Can Perform Adjuvant Chemotherapy Treatment for Gastric Cancer? A Multicenter Retrospective Overview of the Current Status in Korea.

Authors:  Jae-Seok Min; Chang Min Lee; Sung Il Choi; Kyung Won Seo; Do Joong Park; Yong Hae Baik; Myoung-Won Son; Won Hyuk Choi; Sungsoo Kim; Kyung Ho Pak; Min Gyu Kim; Joong-Min Park; Sang Ho Jeong; Moon-Soo Lee; Sungsoo Park
Journal:  J Gastric Cancer       Date:  2018-09-07       Impact factor: 3.720

7.  The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial.

Authors:  Qun Zhao; Changhong Lian; Zhibin Huo; Ming Li; Yang Liu; Liqiao Fan; Bibo Tan; Xuefeng Zhao; Zhidong Zhang; Dong Wang; Yu Liu; Honghai Guo; Peigang Yang; Yuan Tian; Yong Li
Journal:  Cancer Med       Date:  2020-06-24       Impact factor: 4.452

8.  Impact of Palliative Gastrectomy in Patients with Incurable Gastric Cancer.

Authors:  Ji Yeon Park; Byunghyuk Yu; Ki Bum Park; Oh Kyoung Kwon; Seung Soo Lee; Ho Young Chung
Journal:  Medicina (Kaunas)       Date:  2021-02-26       Impact factor: 2.430

9.  Association Among Blood Transfusion, Postoperative Infectious Complications, and Cancer-Specific Survival in Patients with Stage II/III Gastric Cancer After Radical Gastrectomy: Emphasizing Benefit from Adjuvant Chemotherapy.

Authors:  Hua Xiao; Yanping Xiao; Pan Chen; Hu Quan; Jia Luo; Gang Huang
Journal:  Ann Surg Oncol       Date:  2020-09-14       Impact factor: 5.344

10.  Neoadjuvant chemotherapy-induced severe neutropenia is associated with histopathological response and survival in locally advanced gastric cancer.

Authors:  Chaorui Wu; Tongbo Wang; Hong Zhou; Xiaojie Zhang; Chunguang Guo; Yingtai Chen; Dongbing Zhao
Journal:  Transl Cancer Res       Date:  2020-01       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.